Authors: McLeod, D Zinner, N Tomera, K Gleason, D Fotheringham, N Campion, M Garnick, MB

Citation: D. Mcleod et al., A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer, UROLOGY, 58(5), 2001, pp. 756-761

Authors: Van Kerrebroeck, P Kreder, K Jonas, U Zinner, N Wein, AN

Citation: P. Van Kerrebroeck et al., Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder, UROLOGY, 57(3), 2001, pp. 414-421

Authors: Appell, RA Sand, P Dmochowski, R Anderson, R Zinner, N Lama, D Roach, M Miklos, J Saltzstein, D Boone, T Staskin, DR Albrecht, D

Citation: Ra. Appell et al., Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study, MAYO CLIN P, 76(4), 2001, pp. 358-363

Authors: Tomera, K Gleason, D Gittelman, M Moseley, W Zinner, N Murdoch, M Menon, M Campion, M Garnick, MB

Citation: K. Tomera et al., The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer, J UROL, 165(5), 2001, pp. 1585-1589

Authors: Versi, E Defever, M Hu, TW Kobelt, G Moore, K Subak, L Zinner, N

Citation: E. Versi et al., Socio-economic consideration, INCONTINENCE, 1999, pp. 869-891